Clinical trials: Monocytes
Glioblastoma Multiforme
Dendritic Cell Cancer Vaccine for High-grade Glioma
A randomised, open-label, 2-arm, multi-centre, phase II clinical study with one group receiving standard therapy with Temozolomide, radiotherapy, and Trivax; and a control group receiving standard therapy with Temozolomide and…
- Trial name
- GBM-Vax (NCT01213407)
- Testing
- Trivax, Temozolomide, Surgery, Radiotherapy, Temozolomide, Surgery, Radiotherapy
- Where
- 8 sites in Austria
- Volunteers
- 87 people
- Sponsor
- Activartis Biotech
Poorly Controlled Diabetes Mellitus
Changes in Hematological Parameters With Glycemia Control in Type 2 Diabetes
There is a systemic low-grade chronic inflammation in diabetes, and research suggests that this inflammation plays a vital role in the development of diabetic complications.
- Trial name
- NCT06228898
- Where
- Turkey (Türkiye)
- Volunteers
- 170 people
- Sponsor
- Goztepe Prof Dr Suleyman Yalcın City Hospital
Postoperative Wound Infection, Postoperative Outcome
Effect of Perioperative Hemodynamic Optimization on the Immune Function Parameters of Peripheral Blood Monocytes After Cardiac Surgery
Cardiac surgery patients have a high risk to suffer from postoperative infections. Some studies have shown, that humoral and cellular factors are associated with perioperative immunodysfunction and can increase the risk of…
- Trial name
- Algebra (NCT01184430)
- Testing
- Pulse contour cardiac output device
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Chronic Myeloproliferative Disorders, Leukemia
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
RATIONALE: Drugs used in chemotherapy, such as clofarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00293410
- Testing
- clofarabine, cyclophosphamide
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and the best dose of lenalidomide when given together with combination chemotherapy in treating patients with relapsed or refractory acute myeloid leukemia.
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)
- Trial name
- NCT01904643
- Testing
- lenalidomide, mitoxantrone hydrochloride, etoposide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Immunosenescence, Aging
The Immu-KNEE-ty Study
The goal of this observational study is to determine changes in immune functioning after total knee replacement surgery in elderly.
- Trial name
- NCT05920148
- Testing
- Knee arthroplasty
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Wageningen University
Growth Hormone Deficiency
Gene Expression in Monocytes of Growth Hormone Deficient Children
The Growth hormone (GH) is mainly synthesized in the anterior portion of the pituitary gland and has an effect on different body areas.
- Trial name
- GEMGH (NCT04352712)
- Testing
- blood sampling
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Salerno
Sjogren's Syndrome, Autoimmune Diseases
Exploratory Study of the Efficacy of HuMoSCs (Human Monocyte-derived Suppressor Cells) on Glandular Involvement in Sjögren's Syndrome
Sjögren's syndrome is an autoimmune disease. Dry syndrome is a key feature of this condition, almost always leading to dryness of the mouth and eyes.
- Trial name
- Immuno-DRYve (NCT07861828)
- Testing
- Blood sample, Salivary gland biopsy
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Leukemia, Myelodysplastic Syndromes
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
RATIONALE: Bexarotene may help cancer or abnormal cells become more like normal cells, and to grow and spread more slowly. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00425477
- Testing
- sargramostim, bexarotene, cytogenetic analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia
Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00295841
- Testing
- clofarabine, cytarabine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia
S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
RATIONALE: Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00049179
- Testing
- cytarabine, gemtuzumab ozogamicin
- Where
- 151 sites in United States
- Volunteers
- 33 people
- Sponsor
- SWOG Cancer Research Network
Leukemia
A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia
RATIONALE: Drugs used in chemotherapy, such as cytarabine and clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01656031
- Testing
- clofarabine, cytarabine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Wake Forest University Health Sciences
Heart Diseases
Monocyte Priming When Consuming a Western Diet
To determine the mechanism of monocyte priming in humans, the study team will conduct a complete feeding trial in normal weight and metabolically healthy human subjects (20-45 years of age) using a western diet (WD)…
- Trial name
- NCT05348395
- Testing
- Experimental diet
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Leukemia
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as gemtuzumab ozogamicin can locate cancer cells and either kill them or deliver…
- Trial name
- NCT00005962
- Testing
- sargramostim, cyclophosphamide, cytarabine
- Where
- 65 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Leukemia, Myelodysplastic Syndrome
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
RATIONALE: Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bortezomib together with vorinostat may kill more cancer cells.
- Trial name
- NCT00818649
- Testing
- bortezomib, vorinostat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Epithelial Tumors, Malignant
Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
MYE Symphony is a multicenter, open-label, Phase 1 first-in-human study to assess the safety, tolerability, and define the RP2D of MT-302 in participants with advanced epithelial cancer.
- Trial name
- MYE Symphony (NCT05969041)
- Testing
- MT-302 (A)
- Where
- 6 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myeloid Therapeutics
Acute Monocytic Leukemia, Newly Diagnosed
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
This study is to investigate the therapeutic efficacy and side effect of venetoclax, azacytidine combined with chidamide for newly diagnosed acute monocytic leukemia patients that are ineligible for intensive chemotherapy
- Trial name
- NCT05566054
- Testing
- Chidamide, Azacitidine, Venetoclax
- Where
- China
- Volunteers
- 92 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Non-healing Wound
Mechanisms Underlying Impaired Diabetic Wound Healing
The overall aim of this research is to utilize wound derived inflammatory cells from diabetic versus non diabetic human chronic wounds to understand mechanisms that are responsible for disregulated inflammation in individuals…
- Trial name
- WoundVAC (NCT00777712)
- Testing
- Blood draw
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Pittsburgh
Healthy
Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children
Severe acute respiratory syndrome (SARS) is a new emerging infectious disease. Its pathogen is a newly discovered coronavirus (SARS-CoV).
- Trial name
- NCT00173563
- Where
- Taiwan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Cutaneous Leishmaniasis
Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis
The present study was designed as a randomized, single blind, placebo-controlled, study to evaluate the effect of 400 µg of recombinant human GM-CSF applied intralesionally and associated with half of the total dose of antimony…
- Trial name
- GMCSFSbv (NCT00973128)
- Testing
- GMCSF plus Antimony reduced dose, Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Hospital Universitário Professor Edgard Santos